Asthma News - May 22, 2025

Current asthma research, announcements and opportunities, collected and distributed by Michigan Department of Health & Human Services (MDHHS) Asthma Program Staff. Sign up to receive weekly-ish news emails.

Check out the most recent MDHHS asthma social media messages and share them with your networks.

Webinar: FDA Proposed Rule on Low Nicotine Tobacco Products: Michigan’s Role ~ June 3 @ 10 AM

Tobacco Free Michigan and the MDHHS Tobacco Control Program are teaming up to offer a webinar discussing the U.S. Food and Drug Administration’s proposed rule to prohibit low nicotine tobacco products. The webinar will provide an overview of the proposed rule, the rulemaking process, the potential impact, and how individuals and organizations can take action.

EPA Webinar: Wildfire Smoke Air Monitoring Response Technology and AirNow Fire and Smoke Map ~ June 5 @ 3 PM

Wildfires are a major source of poor air quality across the U.S. This webinar will showcase the Wildfire Smoke Air Monitoring Response Technology (WSMART) and AirNow Fire and Smoke Map. These tools can assist in receiving and interpreting near real-time air quality information during wildfires and smoke events, and provide steps to take to reduce exposure and protect health.

Can Chronic Asthma Be Reversed? Experts Reopen the Debate

Learn what air pollution is, the link between childhood asthma and air pollution and how to reduce the risk of asthma flare-ups due to air pollution.

Azithromycin does not reduce illness severity in preschoolers with severe wheezing

Illness severity of preschoolers presenting to the ED for severe wheezing did not differ between 5-day azithromycin and placebo, and futility analyses stopped this trial early. Being negative or positive for bacteria considered pathogenic did not change the illness severity finding.

Severe Asthma Questionnaire and Asthma Control Questionnaire as Early Predictors of Biologic Response in Severe Asthma

This study provides evidence of the early and sustained improvement in health-related quality of life and symptoms after starting biologic therapy. The findings support the use of the Severe Asthma Questionnaire and the Asthma Control Questionnaire as per the Core Outcome Measures Sets for Severe Asthma (COMSA).

Prevalence and clinical impact of asthma-COPD overlap (ACO) in severe asthma

The prevalence of ACO in our multicenter cohort study on severe asthma was approximately 30%. The presence of ACO was not an independent risk for exacerbations or decline in FEV1.